Before revision: doi|10.3389/fmicb.2021.707290ÇÇ ColoAd1 from PsiOxus Therapeutics has entered Phase I/II clinical study with its oncolytic vaccine.
After revision: ColoAd1 from PsiOxus Therapeutics has entered Phase I/II clinical study with its oncolytic vaccine.